echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Hydroxychloroquine can actually affect mortality in patients with systemic lupus erythematosus

    Hydroxychloroquine can actually affect mortality in patients with systemic lupus erythematosus

    • Last Update: 2022-10-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Hydroxychloroquine (HCQ) is almost universally recommended in patients with SLE


     

    Methods: Investigators conducted a nested case-control study


    Features of systemic lupus erythematosus death cases and life controls:

    Results: In 6,241 patients with LE, 290 deaths and 502 matching SLE controls were identified


     

    In summary, in this study nested in the general population-based SLE event cohort, current use of HCQ was found to have significant survival benefits


     

    References: Jorge A, McCormick N, Lu N, Zheng Y, Esdaile J, De Vera M, Choi H, Aviña-Zubieta JA.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.